drugset / Trial / NCT01457664

A Study of RO4995819 in Healthy Elderly Volunteers

NCT01457664

Phase 1 Completed 30 enrolled Hoffmann-La Roche
RandomizedSingle-groupDouble-blindTreatment

Summary

This study will evaluate the safety, tolerability and pharmacokinetics of RO4995819 in healthy elderly volunteers. Volunteers will be randomized to receive once daily doses of RO4995819 or matching placebo. The anticipated time on study treatment is 14 days.

Timeline

Start
2011-07
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject RO4995819 Small molecule Oral

Indications

No indication recorded.